Quantitative analysis of MMR deficiency in dMMR/MSI high CRC and levels of instability: Implications for ICI therapy of dMMR tumors. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adjuvant ...
The FDA approved enfortumab vedotin and pembrolizumab for MIBC, following a priority review of their sBLA for neoadjuvant and ...
Liposomal gemcitabine in combination with pembrolizumab shows promise in the treatment of advanced solid tumors, according to a study presented at the recent American Society of Clinical Oncology ...
One of the best ways to defeat cancer is by rousing the immune system to attack it. Experts have thought that immune cells had to be inside of tumors for one type of immunotherapy, known as checkpoint ...
New longer-term results show a survival benefit from adding the immune checkpoint inhibitor pembrolizumab (Keytruda) to first-line chemotherapy for women with metastatic triple-negative breast cancer ...
With the American Society of Clinical Oncology (ASCO) Annual Meeting right upon us and so much to see, we now need to prioritize the top abstracts to see with the limited time and attention that we ...
Considered to be one of the greatest revolutions in cancer treatment, immunotherapy enhances the immune system's ability to target and destroy cancer cells efficiently. One of the key challenges in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback